• OPEN AN ACCOUNT
Indian Indices
Sensex
85,408.70 -116.14
( -0.14%)
Global Indices
Nasdaq
48,752.17 288.75
(0.60%)
Dow Jones
6,952.35 21.56
(0.31%)
Hang Seng
50,381.79 37.69
(0.07%)
Nikkei 225
9,870.68 -18.54
(-0.19%)
Forex
USD-INR
89.57 -0.04
(-0.05%)
EUR-INR
105.52 0.34
(0.32%)
GBP-INR
120.86 0.52
(0.43%)
JPY-INR
0.57 0.00
(0.60%)

EQUITY - MARKET SCREENER

Bhanderi Infracon Ltd
Industry :  Construction
BSE Code
ISIN Demat
Book Value()
538576
INE336Q01016
98.6929061
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
41.13
39.73
EPS(TTM)
Face Value()
Div & Yield %
3.72
10
0
 

Alembic receives USFDA approval for Travoprost Ophthalmic Solution
Dec 18,2025

Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution). The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Travatan Z Ophthalmic Solution, 0.004%, of Sandoz Inc. (Sandoz). Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Travoprost Ophthalmic Solution USP, 0.004%, has an estimated market size of US$ 61 million for twelve months ending September 2025 according to IQVIA.

Alembic has a cumulative total of 232 ANDA approvals (212 final approvals and 20 tentative approvals) from USFDA.